אילאריס 150 מגמל תמיסה להזרקה ישראל - עברית - Ministry of Health

אילאריס 150 מגמל תמיסה להזרקה

novartis israel ltd - canakinumab - תמיסה להזרקה - canakinumab 150 mg / 1 ml - canakinumab

אילאריס 150 מגמל ישראל - עברית - Ministry of Health

אילאריס 150 מגמל

novartis israel ltd - canakinumab - אבקה להכנת תמיסה לזריקה - canakinumab 150 mg / 1 ml - canakinumab - canakinumab - cryopyrin - associated periodic syndromes (caps) in adults, adolescents and children aged 2 years and older with body weight above 7.5 kg, including : - mucle - wells syndrome (mws), - neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca), - severe forms of familial cold autoinflammatory syndrome (fcas) / familial cold urticaria (fcu) presenting with signs and symptoms beyond cold-induced urticarial skin rash.gouty arthritis:ilaris is indicated for the symptomatic treatment of adults patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (nsaids) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.